Vertex Pharmaceuticals Incorporated company logo

# RNN 1st Gen Model Vertex Pharmaceuticals Incorporated Pharmaceutical preparations

Prediction models:
Subscribe >> Deal exit on
Feb. 22, 2018
Deal entry on
Feb. 22, 2018
0.54%Expected margin
71.15% successful of 52 deals
$ 157.89 Last close price
at 21-feb-2018

VRTX

Model's trade recommendations 10.20% Return for period

5.96% Annual return

$40.87B Market Cap

β 1.61  

VRTX

Model (following trade recommendations)

VRTX

Underlying stock

S&P 500

Index
Return for period 10.20%
-5.71%
1.78%
52wk return 25.60%
84.04%
16.82%
52wk Range
85.73—172.66
2000.54—2399.63
Sortino ratio 0.45
Sharpe ratio 0.37
Norm. RMSE 0.93%
Downside risk 18.18%
Volatility 22.01%
  • STRONG BUY Analysts consensus recommendation

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Vertex Pharmaceuticals Incorporated (VRTX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for VRTX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 249M
P/E 203.77
Shares Outstanding 254M
% Held by Insiders 1.80%
% Held by Institutions 94.10%
EPS (last reported FY) $0.80
EPS (last reported Q) $0.32
EPS, estimated (last reported Q) $0.29
Total revenues $2 B
Net income $0 B